Valeo Pharma, Inc. Quarterly Results: Standalone & Consolidated Reports

Quarterly Results

Results Snapshot

YoYQoQ

Figures in Million

Consolidate Quarterly Results

Jul'24

Apr'24

Jan'24

Oct'23

Jul'23

Apr'23

Jan'23

Net Sales

12.60

14.13

13.54

13.11

14.08

13.56

13.16

Other Operating Income

0.00

Total Operating income

12.60

14.13

13.54

13.11

14.08

13.56

13.16

Raw Material Cost

9.70

11.38

11.44

12.79

10.02

9.27

9.62

Purchase of Finished goods

0.00

(Increase) / Decrease In Stocks

0.00

Employee Cost

3.36

4.07

4.17

4.51

4.52

4.75

5.05

Power Cost

0.00

Manufacturing Expenses

4.89

3.85

3.75

3.76

3.46

3.34

3.26

Selling and Distribution Expenses

6.12

6.64

6.96

7.46

7.49

7.09

7.41

Other Expenses

-0.82

-0.79

-0.83

-0.80

-0.81

-0.83

Total Expenditure (Excl Depreciation)

15.82

18.02

18.40

20.24

17.51

16.36

17.02

Operating Profit (PBDIT) excl Other Income

-3.2

-3.9000000000000004

-4.9

-7.1

-3.4000000000000004

-2.8000000000000003

-3.9000000000000004

Other Income

-0.08

-0.07

1.74

1.65

1.05

-0.55

0.78

Operating Profit (PBDIT)

-2.68

-3.32

-2.48

-4.73

-1.75

-2.72

-2.47

Interest

4.89

3.85

3.75

3.76

3.46

3.34

3.26

Exceptional Items

0.00

0.21

0.10

Gross Profit (PBDT)

2.90

2.75

2.10

0.32

4.06

4.29

3.54

Depreciation

0.63

0.64

0.65

0.75

0.63

0.62

Profit Before Tax

-8.19

-7.81

-6.87

-9.24

-5.84

-6.48

-6.25

Tax

0.00

Provisions and contingencies

0.00

Profit After Tax

-8.19

-7.81

-6.87

-9.24

-5.84

-6.48

-6.25

Extraordinary Items

0.00

Prior Period Expenses

0.00

Other Adjustments

0.00

Net Profit

-8.19

-7.81

-6.87

-9.24

-5.84

-6.48

-6.25

Share in Profit of Associates

0.00

Minority Interest

0.00

Other related items

0.00

Consolidated Net Profit

-8.19

-7.81

-6.87

-9.24

-5.84

-6.48

-6.25

Equity Capital

0.00

Face Value

0.0

Reserves

-63.03

-54.87

-47.01

-40.34

-35.05

-29.16

-23.57

Earnings per share (EPS)

-0.08

-0.1

-0.07

-0.08

Diluted Earnings per share

-0.08

-0.1

-0.07

-0.08

Operating Profit Margin (Excl OI)

-25.55%

-27.55%

-35.92%

-54.42%

-24.36%

-20.67%

-29.34%

Gross Profit Margin

-60.04%

-50.78%

-45.94%

-64.8%

-36.98%

-43.14%

-42.78%

PAT Margin

-65.01%

-55.28%

-50.76%

-70.53%

-41.46%

-47.77%

-47.47%

Public Share Holdings (%)

0.0%

Pledged Promotor Holding (%)

0.0%

Quarterly Analysis Highlights - QoQ

Net Sales

QoQ Growth in quarter ended Jul 2024 is -10.64% vs 4.44% in Apr 2024

Consolidate Net Profit

QoQ Growth in quarter ended Jul 2024 is -5.13% vs -13.04% in Apr 2024

Operating Profit (PBDIT) excl Other Income

QoQ Growth in quarter ended Jul 2024 is 21.21% vs 21.43% in Apr 2024

Interest

QoQ Growth in quarter ended Jul 2024 is 25.64% vs 5.41% in Apr 2024

Operating Profit Margin (Excl OI)

QoQ Growth in quarter ended Jul 2024 has improved from Apr 2024

Compare Quarterly Results Of Valeo Pharma, Inc. With

Select Peers

Figures in Million

Consolidate Quarterly Results

Change(CAD)

Change(%)

Net Sales

12.60

0.03

12.57

41,900.00%

Other Operating Income

0.00

Total Operating income

12.60

0.03

12.57

41,900.00%

Raw Material Cost

9.70

0.08

9.62

12,025.00%

Purchase of Finished goods

0.00

(Increase) / Decrease In Stocks

0.00

Employee Cost

3.36

0.17

3.19

1,876.47%

Power Cost

0.00

Manufacturing Expenses

4.89

0.00

4.89

Selling and Distribution Expenses

6.12

0.42

5.70

1,357.14%

Other Expenses

-0.82

-0.02

-0.80

-4,000.00%

Total Expenditure (Excl Depreciation)

15.82

0.49

15.33

3,128.57%

Operating Profit (PBDIT) excl Other Income

-3.22

-0.46

-2.76

-600.00%

Other Income

-0.08

0.01

-0.09

-900.00%

Operating Profit (PBDIT)

-2.68

-0.41

-2.27

-553.66%

Interest

4.89

0.00

4.89

Exceptional Items

0.00

Gross Profit (PBDT)

2.90

-0.05

2.95

5,900.00%

Depreciation

0.63

0.05

0.58

1,160.00%

Profit Before Tax

-8.19

-0.46

-7.73

-1,680.43%

Tax

0.00

Provisions and contingencies

0.00

Profit After Tax

-8.19

-0.46

-7.73

-1,680.43%

Extraordinary Items

0.00

Prior Period Expenses

0.00

Other Adjustments

0.00

Net Profit

-8.19

-0.46

-7.73

-1,680.43%

Share in Profit of Associates

0.00

Minority Interest

0.00

Other related items

0.00

Consolidated Net Profit

-8.19

-0.46

-7.73

-1,680.43%

Equity Capital

0.00

Face Value

0.00

Reserves

-63.03

1.62

-64.65

-3,990.74%

Earnings per share (EPS)

-0.08

-0.00

-0.08

Diluted Earnings per share

-0.08

-0.00

-0.08

Operating Profit Margin (Excl OI)

-25.55%

-1,619.48%

0.00

1,593.93%

Gross Profit Margin

-60.04%

-1,441.60%

0.00

1,381.56%

PAT Margin

-65.01%

-1,599.78%

0.00

1,534.77%

Public Share Holdings (%)

0.00

0.00%

Pledged Promotor Holding (%)

0.00

0.00%

Quarterly - Net Sales

Net Sales 1.26 Million

in Jul 2024

Figures in Million

QoQ Growth in quarter ended Jul 2024 is -10.64% vs 4.44% in Apr 2024

YoY Growth in quarter ended Jul 2024 is -10.64% vs 131.15% in Jul 2023

Quarterly - Consolidate Net Profit

Consolidate Net Profit -0.82 Million

in Jul 2024

Figures in Million

QoQ Growth in quarter ended Jul 2024 is -5.13% vs -13.04% in Apr 2024

YoY Growth in quarter ended Jul 2024 is -41.38% vs -7.41% in Jul 2023

Quarterly - Operating Profit (PBDIT)

Operating Profit (PBDIT) -0.26 Million

in Jul 2024

Figures in Million

QoQ Growth in quarter ended Jul 2024 is 21.21% vs 21.43% in Apr 2024

YoY Growth in quarter ended Jul 2024 is 7.14% vs 26.32% in Jul 2023

Quarterly - Interest

Interest 0.49 Million

in Jul 2024

Figures in Million

QoQ Growth in quarter ended Jul 2024 is 25.64% vs 5.41% in Apr 2024

YoY Growth in quarter ended Jul 2024 is 40.00% vs 191.67% in Jul 2023

Quarterly - Operating Profit Margin (Excl OI)

Operating Profit Margin (Excl OI) -25.55%

in Jul 2024

Figures in %

QoQ Growth in quarter ended Jul 2024 has improved from Apr 2024

YoY Growth in quarter ended Jul 2024 has fallen from Jul 2023